AzTrials
AzTrials

Chronic Total Occlusion of Arteries of the ExtremitiesPROSPECTORNCT03266835

SoundBite™ Crossing System Pivotal Peripheral CTO Crossing Study

A study testing SoundBite™ Crossing System - Peripheral in people with Chronic Total Occlusion of Arteries of the Extremities, run by SoundBite Medical Solutions, Inc. at 2 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is aimed at demonstrating the efficacy and safety of the SoundBite™ Crossing System-Peripheral. The study is intended to demonstrate that the SoundBite™ Crossing System can facilitate the passage of either devices intended to treat a chronic total occlusion (CTO) or additional crossing devices through an… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
SoundBite™ Crossing System - Peripheral
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
15 participants
Where
2 sitesin 2 countries
Study dates
16 Nov 2017to 18 Jan 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

General Inclusion Criteria:

  1. Has symptomatic chronic limb ischemia, requiring treatment of an in:frainguinal artery
  2. Has Rutherford Clinical Category of 2-5
  3. Is ≥ 18 years old
  4. Has life expectancy > 1 year
  5. Is able and willing to provide written informed consent prior to study procedure

Angiographic Inclusion Criteria:

Unless otherwise specified, the Investigator performing the procedure bases angiographic inclusion on visual determination of qualification imaging taken at time of procedure.

Subject must meet ALL the following angiographic inclusion criteria:

  1. Has evidence of a clinically significant de novo CTO located in a peripheral vessel below the infrainguinal ligament confirmed by angiography at time of procedure.
  2. Notwithstanding criteria 1, multilevel CTOs are included as long as the total length from the beginning of the most proximal total occlusion to the end of the most distal total occlusion is less than 40 cm.
  3. 100% stenosis by visual estimate of angiography at time of procedure.
  4. Has target limb with at least one patent (<50% stenosis) run-off vessel confirmed by angiography or magnetic resonance angiography at time of procedure.

General Exclusion Criteria:

  1. Has had a previous peripheral bypass that includes the target vessel.
  2. Has had a previous intervention on the target CTO (e.g., angioplasty, stent placement), including previous attempt at time of index procedure.
  3. History of any vascular procedure on the index limb within the last 30 days requiring clinically driven re-intervention.
  4. Has an active infection in the target limb.
  5. Subject has any planned major surgical or interventional procedure within 30 days after the study procedure.
  6. Has received a kidney transplant.
  7. Glomerular Filtration Rate (GFR) of less than 40.
  8. Unstable coronary artery disease or other uncontrolled comorbidity.
  9. Myocardial infarction or stroke within 2 months prior to baseline evaluation.
  10. Subject has positive pregnancy test result in women of child bearing potential or is breast-feeding.
  11. Participation in any study of an investigational device, medication, biologic, or other agent during study or within 30 days prior to enrollment that is either a cardiovascular study or could, in the judgment of the investigator, affect the results of this study.
  12. Subject in whom antiplatelet, anticoagulant therapy is contraindicated
  13. Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/ml or known coagulopathy.
  14. Known, untreated allergy to contrast agents or medications used during or subsequent to endovascular intervention. Patients with aspirin allergy that have been desensitized are not excluded.
  15. History of heparin-induced thrombocytopenia (HIT) that cannot be treated with direct thrombin inhibitors.
  16. Any thrombolytic therapy within two weeks prior to enrollment.
  17. Psychiatric disorder which in the judgment of the investigator could interfere with provision of informed consent, completion of tests, therapy, follow-up or general study compliance Angiographic Exclusion Criteria Unless otherwise specified, the Investigator performing the procedure bases angiographic exclusion on visual determination of qualification imaging taken up to 6 months prior to procedure and/or imaging taken at time of procedure. Subject is excluded if ANY of the following angiographic exclusion criteria is met:
  18. Has significant stenos is or occlusion of inflow tract ( upstream disease) unsuccessfully treated at time of index procedure or presenting symptoms such as embolism confirmed by angiography.
  19. Has in a native vessel, a previously stented segment separated by < 3 cm of angiographically normal vessel from the target CTO.
  20. CTOs lacking at least one patent target distal artery (::;SO% diameter stenosis).
  21. Has an acute or sub-acute intraluminal thrombus within the target vessel.
  22. Aneurysm distal to puncture access site at least twice the reference vessel diameter, located in the index vessel, abdominal aorta, iliac or popliteal.
  23. Has perforation, dissection or other injury of the access site or index vessel requiring stenting or surgical intervention prior attempting crossing of the target lesion with SoundBite™ Crossing System.
  24. Clinical/angiographic evidence of distal embolization in the index extremity.

Trial locations and contacts

2 sites in 2 countries.

2 sites in 2 countries

United States1 site
  • UNC Rex Healthcare

    Raleigh, North Carolina, 27607

Other trials in United States

Canada1 site
  • CHUM-Hôtel-Dieu du Centre Hospitalier Universitaire de Montréal

    Montreal, Quebec, H2W 1T8

Other trials in Canada

About this study

Official title: A Multinational, Single-Arm Pivotal Study to Assess the Performance Rate Of SoundBite™ Active Wire for PEripheral Chronic Total Occlusion Recanalization (PROSPECTOR)

This study is aimed at demonstrating the efficacy and safety of the SoundBite™ Crossing System-Peripheral. The study is intended to demonstrate that the SoundBite™ Crossing System can facilitate the passage of either devices intended to treat a chronic total occlusion (CTO) or additional crossing devices through an infrainguinal CTO into the true lumen.

Read the detailed description

This is a multinational, single-arm, pivotal trial assessing the efficacy and safety of the SoundBite™ Crossing System - Peripheral. The enrollment will consist of up to 100 patients meeting the inclusion/exclusion criteria in order to obtain 90 evaluable patients for efficacy and safety analysis. The primary endpoints will be compared to literature-based performance goals to establish study success.

Objective Performance Goals (OPG) have been obtained from a literature based review. Reports published in the past 10 years were reviewed for both safety and effectiveness in crossing infrainguinal CTO. The studies reviewed generally have one primary composite safety endpoint and one primary efficacy endpoint. Some studies have performed formal hypothesis testing versus a pre-specified performance goal for one or both endpoints.

Being tested
SoundBite™ Crossing System - Peripheral
Keywords
Chronic Total Occlusion, Peripheral, SoundBite™ Crossing System, CTO, intra-luminal, Active wire, Device, Procedure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SoundBite™ Crossing System - PeripheralDevice

    SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.

Study groups in NCT03266835
Study groupRoleWhat they receive
SoundBite™ Crossing System - PeripheralOtherThis is a multinational, single-arm, pivotal trial assessing the efficacy and safety of the SoundBite™ Crossing System with subjects diagnosed with de novo infrainguinal arterial chronic total occlusion(s).
Receives: Device: SoundBite™ Crossing System - Peripheral

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Technical Device Success

    Ability to facilitate treatment of the target lesion by allowing additional crossing and/or treatment devices to cross the CTO

    Measured: Day 1

  2. Freedom from SoundBite™ Crossing System related MAEs at 30 days post procedure

    MAEs defined as:

    • Cardiovascular related deaths
    • Unplanned, index limb amputation
    • Dissection of grade C or greater that require an intervention to resolve
    • Symptomatic distal embolization, defined as clinical signs or symptoms of distal emboli detected in the treated limb distal to the treated lesion after the index procedure or noted angiographically after the index procedure, and requiring mechanical or pharmacologic means to improve flow

    Measured: up to Day 30

Secondary outcomes (5)
  1. Procedural success

    Achievement of Technical Success together with post-procedural patency. Post-procedural patency is defined as less then or equal to 50% residual percent diameter stenosis assessed by visual estimate at the end of revascularization procedure

    Measured: Day 1

  2. Clinical Success

    Achievement of Procedural Success as well as freedom from SoundBite™ Crossing System related MAEs at 30 days

    Measured: Up to Day 30

  3. Penetration ≥ 0.5 cm

    Ability of the SoundBite™ Crossing System to penetrate ≥ 0.5 cm of any segment of the CTO

    Measured: Day 1

  4. Fully traverse

    Ability of the SoundBite™ Crossing System to fully traverse the CTO with entry into the distal true lumen without the need for additional guidewires and/or re-entry devices

    Measured: Day 1

  5. Freedom from any SoundBite™ Crossing System related Adverse Events

    Freedom from any SoundBite™ Crossing System related Adverse Events

    Measured: Up to Day 30

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Aug 2017
  2. Study start16 Nov 2017
  3. Primary completion18 Jan 2019
  4. Study completion18 Jan 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
15 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03266835
Sponsor's protocol ID
NAP-PER-2017-01
Acronym
PROSPECTOR
Status last verified
Apr 2019
First submitted
25 Aug 2017
Last updated
25 Apr 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing SoundBite™ Crossing System - Peripheral in people with Chronic Total Occlusion of Arteries of the Extremities, run by SoundBite Medical Solutions, Inc. at 2 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Technical Device Success (time frame: Day 1). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Apr 2019.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in